Heme arginate
| Identifiers | |
|---|---|
|  100438-92-4  | |
| MeSH | Heme+arginate | 
| PubChem | 3086464 | 
| Properties | |
| C40H48FeN8O6+2 | |
| Molar mass | 792.704 | 
|   Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).  | |
|   | |
| Infobox references | |
Heme arginate (or haem arginate) is a compound of heme and arginine used in the treatment of acute porphyrias.[1][2] This heme product is only available outside the United States and is equivalent to hematin.[3]
Heme arginate is a heme compound, whereby L-arginine is added to prevent rapid degradation. It is given intravenously, and its action of mechanism is to reduce the overproduction of δ-aminolevulinic acid, which can cause the acute symptoms in an attack of the acute porphyrias. [4]
See also
References
- ↑ "HAEM ARGINATE FOR THE ACUTE ATTACK OF PORPHYRIA". Porphyria South Africa.
 - ↑ "Treatment of the Acute Attack". European Porphyria Network. Retrieved 28 August 2011.
 - ↑ "Panhematin for Acute Porphyria". American Porphyria Foundation. Retrieved 28 August 2011.
 - ↑ Volin, L; V Rasi; E Vahtera; R Tenhunen (1988). "Heme arginate: effects on hemostasis" (PDF). Blood Journal 71: 625–628. Retrieved 28 August 2011.
 
This article is issued from Wikipedia - version of the Tuesday, July 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.